SCHEMBL29601755

SCHEMBL29601755

Cc1cccnc1C(=O)Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 1/20 0.45
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.44
CYP1A2 P05177 1/20 0.44
CTSA P10619 1/20 0.43
CES1 P23141 2/20 0.42
CES2 O00748 1/20 0.42
AKR1B1 P15121 1/20 0.42
POLB P06746 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
CTNNB1 P35222 1/20 0.42
WNT3A P56704 1/20 0.42
GAA P10253 1/20 0.42
NPC1 O15118 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
ATM Q13315 1/20 0.42
KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27039672 1.00 LMNA (0.45) LMNASMN1; SMN2HPGDMAPTKDM4E
Bromide SCHEMBL27040139 0.98 LMNA (0.44) LMNASMN1; SMN2HPGDMAPTKDM4E
Bromide SCHEMBL29601637 0.98 LMNA (0.44) LMNASMN1; SMN2HPGDMAPTKDM4E
SCHEMBL5312789 0.79 BRD4 (0.43) SMN1; SMN2HPGDMAPTKDM4ECYP1A2
SCHEMBL15988730 0.79 CTNNB1 (0.60) LMNASMN1; SMN2MAPTCYP1A2POLB
SCHEMBL29601119 0.77 RAB9A (0.41) SMN1; SMN2MAPTKDM4ECYP1A2CTSA
SCHEMBL3701074 0.77 RAB9A (0.41) SMN1; SMN2MAPTKDM4ECYP1A2CTSA
SCHEMBL2479225 0.77 CTNNB1 (0.49) SMN1; SMN2MAPTKDM4ECYP1A2CTNNB1
SCHEMBL3958929 0.76 KMT2A (0.61) SMN1; SMN2MAPTKDM4EPOLBGAA
SCHEMBL20201222 0.76 POLB (0.57) LMNASMN1; SMN2HPGDMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232449-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-08-30 EP disclosed
CN-116547282-A Heterocyclic compounds and their use for the treatment of helminth infections and diseases 新基公司 2023-08-04 CN disclosed
WO-2022087326-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-04-28 WO disclosed